SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Dov Pharmaceutical, Inc - DOVP
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mopgcw who wrote (126)9/12/2005 11:38:42 AM
From: keokalani'nui  Read Replies (1) of 172
 
Bunionectomy is painful operation.

DOV Pharmaceutical, Inc. Announces Statistically Significant Analgesic Effects of Bicifadine in Phase III Clinical Trial in Patients Following Bunionectomy Surgery
Monday September 12, 7:52 am ET

HACKENSACK, N.J., Sept. 12 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. (Nasdaq: DOVP - News) announced today that bicifadine, its novel non-narcotic and non-NSAID analgesic, provided statistically and clinically significant analgesic effects at 400 mg administered three times daily (t.i.d) relative to a placebo control group. These effects were comparable to the analgesia produced by the active-control tramadol 100 mg t.i.d. in patients with moderate-severe pain following bunionectomy surgery. Bicifadine was well- tolerated with no serious adverse events. This trial is the first of four pivotal Phase III efficacy trials required for submission of a New Drug Application to the Food and Drug Administration (FDA) for an indication in the treatment of acute pain. The current results are consistent with the safety and efficacy findings from two other double-blind, placebo-controlled studies in patients with moderate-severe pain following dental surgery. (snip)

I see in the PR dovp is calling bicifadine a 'chemically novel molecule'.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News